NCT03799913

MESO-CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer

A Clinical Trial of MESO-CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer

• Status: Unknown
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Zhejiang University · Academic / Other
• Sex: Female
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to study the feasibility and efficacy of anti-MESO antigen receptors (CARs) T cell therapy for relapsed and refractory ovarian cancer.

Detailed description

Primary Objectives 1.To determine the feasibility ad safety of anti-MESO CAR-T cells in treating patients with MESO-positive ovarian cancer. Secondary Objectives 1. To access the efficacy of anti-MESO CAR-T cells in patients with ovarian cancer. 2. To determine in vivo dynamics and persistency of anti- MESO CAR-T cells.

Conditions

• Ovarian Cancer

Interventions

Type	Name	Description
BIOLOGICAL	anti-MESO CAR-T cells	Retroviral vector-transduced autologous T cells to express anti-MESO CARs
DRUG	Fludarabine	30mg/m2/d
DRUG	Cyclophosphamide	300mg/m2/d

Timeline

• Start date: 2019-04-10
• Primary completion: 2021-10-01
• Completion: 2022-04-01
• First posted: 2019-01-10
• Last updated: 2019-04-10

Locations

1 site across 1 country: China